ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 49,600 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) Director Laura Shawver sold 49,600 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $11.21, for a total value of $556,016.00. Following the completion of the transaction, the director now directly owns 210,346 shares of the company's stock, valued at approximately $2,357,978.66. This represents a 19.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Laura Shawver also recently made the following trade(s):

• On Monday, February 3rd, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $12.31, for a total transaction of $615,500.00.
• On Monday, January 6th, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $11.10, for a total transaction of $555,000.00.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ SPRY traded up $0.43 during midday trading on Tuesday, hitting $11.26. The company's stock had a trading volume of 521,782 shares, compared to its average volume of 1,321,213. The business's fifty day simple moving average is $11.87 and its two-hundred day simple moving average is $13.11. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -22.02 and a beta of 1.03. ARS Pharmaceuticals, Inc. has a 1 year low of $7.55 and a 1 year high of $18.51.

Remove Ads

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC lifted its stake in ARS Pharmaceuticals by 9.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 57,624 shares of the company's stock worth $836,000 after acquiring an additional 4,810 shares during the last quarter. US Bancorp DE increased its holdings in ARS Pharmaceuticals by 11,951.6% in the third quarter. US Bancorp DE now owns 18,680 shares of the company's stock valued at $271,000 after buying an additional 18,525 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in ARS Pharmaceuticals by 67.7% during the 3rd quarter. GSA Capital Partners LLP now owns 98,900 shares of the company's stock worth $1,434,000 after buying an additional 39,921 shares during the last quarter. Royce & Associates LP boosted its position in shares of ARS Pharmaceuticals by 7.1% during the 3rd quarter. Royce & Associates LP now owns 691,455 shares of the company's stock worth $10,026,000 after acquiring an additional 45,755 shares in the last quarter. Finally, First Turn Management LLC acquired a new position in shares of ARS Pharmaceuticals during the 3rd quarter worth about $8,603,000. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on SPRY shares. Scotiabank started coverage on shares of ARS Pharmaceuticals in a research note on Friday. They set a "sector outperform" rating and a $30.00 price objective for the company. Oppenheimer initiated coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They issued an "outperform" rating and a $40.00 target price for the company. William Blair reaffirmed an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Leerink Partners increased their price target on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. Finally, Raymond James raised their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a "strong-buy" rating in a report on Tuesday, January 14th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $29.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.